Variables | Learning cohort [cases (%)] | Validation cohort [cases (%)] | ||||
---|---|---|---|---|---|---|
High expression | Low expression | P* | High expression | Low expression | P* | |
Age (years) | 0.775 | Â | Â | 0.547 | ||
 ≤ 55a | 22 (40.7) | 32 (59.3) |  | 10 (40.0) | 15 (60.0) |  |
 > 55 | 19 (43.1) | 25 (56.9) |  | 8 (38.0) | 13 (62.0) |  |
Gender | 0.501 | Â | Â | 0.709 | ||
 Male | 34 (41.5) | 48 (58.5) |  | 15 (36.8) | 23 (63.2) |  |
 Female | 7 (43.8) | 9 (56.2) |  | 3 (37.5) | 5 (62.5) |  |
WHO grade | 0.719 | Â | Â | 0.660 | ||
 G1 | 11 (45.8) | 13 (54.2) |  | 4 (36.4) | 7 (63.6) |  |
 G2 | 20 (40.0) | 30 (60.0) |  | 8 (40.0) | 12 (60.0) |  |
 G3/4 | 10 (41.7) | 14 (58.3) |  | 6 (40.0) | 9 (60.0) |  |
Tumor size (cm) | 0.640 | Â | Â | 0.387 | ||
 ≤ 6b | 22 (39.3) | 34 (60.7) |  | 13 (40.7) | 19 (59.3) |  |
 > 6 | 19 (45.2) | 23 (54.8) |  | 5 (35.8) | 9 (64.2) |  |
T category | 0.541 | Â | Â | 0.174 | ||
 T2 | 5 (41.7) | 7 (58.3) |  | 6 (50.0) | 6 (50.0) |  |
 T3 | 14 (40.0) | 21 (60.0) |  | 6 (33.3) | 12 (66.7) |  |
 T4 | 22 (43.1) | 29 (56.9) |  | 6 (37.5) | 10 (62.5) |  |
N category | 0.622 | Â | Â | 0.328 | ||
 N0 | 8 (47.1) | 9 (52.9) |  | 6 (42.9) | 8 (57.1) |  |
 N1 | 33 (40.8) | 48 (59.2) |  | 12 (37.5) | 20 (62.5) |  |
M category | 0.352 | Â | Â | 0.302 | ||
 M0 | 27 (45.8) | 32 (54.2) |  | 10 (41.7) | 14 (58.3) |  |
 M1-lym | 14 (35.9) | 25 (64.1) |  | 8 (31.9) | 14 (68.1) |  |
CRT response | 0.007 | Â | Â | 0.003 | ||
 CR | 14 (73.7) | 5 (26.3) |  | 8 (80.0) | 2 (20.0) |  |
 Not CR | 27 (34.2) | 52 (65.8) |  | 10 (27.8) | 26 (72.2) |  |